www.theannals.com EDITORIAL The article by Schentag et al. 1 in this issue of The Annals is less of a scientific review and more of an unfortunate reflection of ongoing disagreements between themselves and other groups, which is inappropriately obvious. The complete lack of acceptance of data that conflicts with their past findings, as well as misinterpretation of their own data, represents a level of hubris that should neither be tolerated nor supported by the readership and scientific community as a whole. Science is ever-evolving, no matter to which subset researchers apply their scientific fortitude. As such, to accept that there is not more than one approach to a solution is the antithesis of science. The pharmacodynamic concept of 24-hour unbound drug AUC/minimum inhibitory concentration (MIC) has advanced our search for a way to optimize patient outcomes, prevent antimicrobial resistance, and hopefully prevent toxicity. However, this article and ones related to it by the same author(s) stating that the concept (AUC/MIC) is to be used to describe the antibacterial effects for all antiinfectives in its current format, using the breakpoints they have defined, significantly minimizes the impact it might otherwise have in the scientific community.
As evidenced throughout this review, the authors' arguments are self-serving and mistakenly misinterpret the tri-als they discuss, including their own data. As much as the population-based MIC 90 of an organism to an antibiotic may be higher or lower than a patient's actual isolate, these estimates are more accurate on average than the population-based pharmacokinetics that are used in the other half of the optimization equation. Population-based pharmacokinetic values and/or equations that may be used to calculate a 24-hour AUC (i.e., via total clearance equations) 2 are often derived from Phase I healthy volunteer studies rather than from studies of patients with the disease state for which the antibiotic is being used. In contrast, the MIC 90 values are an average of a grouping of clinical isolates and, as such, have somewhat less chance for significant variability regarding the MIC of an individual's pathogen than the individual's pharmacokinetics as calculated from these types of equations. If anything, the MIC is currently a more useful tool in attempts to use these equations at the bedside, as the actual MIC of the individual's pathogen will be available at the end of susceptibility testing 48 hours into the patient's antibiotic regimen (assuming a bacterial infection is present, appropriate cultures were performed, and an organism was identified). In contrast, since it is exceedingly rare to find an institution that can provide rapid turnaround assay results of serum antibiotic samples for fluoroquinolones, let alone the majority of antibiotics, the pharmacokinetic half of the optimization equation will always remain population based. The use of population equations derived from healthy volunteers to estimate drug exposure is at best an educated guess that may or may not be accurate.
A more blatant example of the authors' disdain involves the discussion concerning gram-positive organisms. Although the discussion took up at least twice as much space as discussion of the gram-negative organisms, there was little to no evaluation of the large body of research that has been published on the pharmacodynamics of fluoroquinolones used to treat gram-positive pathogens, let alone Streptococcus pneumoniae. Rather, the article in this issue of The Annals berates the article by Preston et al. 3 for methods that were also used by Schentag et al. 4 in their seminal paper involving ciprofloxacin and providing interpretations that did not exist in the Preston et al. article, combined with some interesting yet completely erroneous interpretations of the pathology of an infection. First, not only did Preston et al. fail to analyze their findings by organism or, at the very least, by gram-positive/gram-negative, but the study by Schentag et al. 4 (that is stated was done more correctly) suffers from the same lack of organism analysis breakdown. The conclusion by Schentag et al. that patients with nosocomial pneumonia lack a host response is completely without basis and is unsupported by the 3 references they use which are, in fact, 2 pharmacokinetic studies and 1 clinical trial that involved immunocompetent patients. 1,4-6 Although many of the patients in these studies certainly had an interruption of a host barrier defense due to the introduction of an endotracheal tube or tracheostomy, the vast majority most certainly had functional immune systems.
The statement that bacterial killing endpoints are only obvious with pneumococcal infections when they take the form of severe pneumonia requiring hospitalization is naïve, again inferring that these types of patients lack any form of immune response and their improvement is solely due to antimicrobial effect. These statements come from a commonly held belief that if such a severe infection develops, the immune system has been overcome and is nonfunctional, and any pathogen eradication at this stage of disease is due solely to the antibiotic. If this adage were true, then it would be true not just for severe pneumonia, as Schentag et al. 1 claim, but also any type of infection, because if the infection is able to manifest itself, it has overcome the balance between colonizers/flora/contaminants and physiologic barriers/immune responses.
If anything, any patient who is not truly immunosuppressed/immunocompromised brings doubt upon the current iteration of the AUC/MIC concept and its breakpoints, which is based on 24-hour serum exposure. This is because the acute reactant cells that respond to an infection stimulus, such as neutrophils and macrophages, have intracellular fluoroquinolone concentrations that are anywhere from 4 to 10 times higher than concurrent extracellular serum concentrations. As this intracellular drug has been demonstrated to be active, this is the actual drug exposure that the pathogen comes in contact with upon phagocytosis and clearance from the blood and/or infection site. 7,8 In addition, recent data suggest an additive or synergistic effect between fluoroquinolones and neutrophils in which the AUC/MIC ratio necessary for optimal outcomes was lower in an immunocompetent host compared with an immunosuppressed host. 9 Based on all of these findings, no matter how severe a patient's infection, one cannot discount the effects of the drug or the immune system in an overall optimization scheme, and the use of serum concentrations for this class of drugs may be an inaccurate oversimplification of a more complex process.
Another inconsistency with the Schentag et al. 1 interpretation of the work by Preston et al. 3 is their recalculation of the maximum concentration/MIC ratio as an AUC/MIC ratio value. Although on average the ratio may have been 110, Drusano et al. 10 noted in a response to a separate criticism of their article 3 by Schentag et al. 11 that over half of the patients who had a positive outcome from a pneumococcal infection actually obtained AUC/MIC ratios below 100. This statement not only provides an additional argument for a separation by genus of the organisms in break point analyses, it also indicates that gram-positive pathogens do indeed respond more commonly to ratios below 100 and certainly well below 250. The criticism by Schentag et al. that the Preston et al. 3 study may be too small is an odd suggestion when their study 4 that they use for comparison against other studies has an even smaller sample size.
The finding of fault with the lack of serial cultures to identify the eradication day is interesting since neither Preston et al. 3 nor Ambrose et al. 12 set out to identify the exact day of eradication. Although scientifically it may be interesting to see whether a pathogen is eradicated on day 2 versus day 4 of therapy, the clinical import of this is ambiguous and can be discordant with clinical outcome. This discordance between eradication of bacteria and clinical response was highlighted in the grepafloxacin analysis Schentag's group published a number of years ago where clinical response was seen in the face of continuing culture positivity. 13 Rather than day of eradication, a clinician and the patient are more concerned with the clinical outcome at the end of therapy and the patient's steady improvement during therapy. Unlike the Schentag et al. 4 data, which had eradication rates exceeding 2-3 weeks in some patients, thereby inferring prolonged treatment courses, the treatment periods used by Preston et al. 3 and Ambrose et al. 12 were ≤14 days. Although eradication may have occurred on day 2 of therapy for a patient with community-acquired pneumonia, it would be a rare clinician who would actually stop therapy at that time rather than complete the 7-to 14-day course as there are few clinical data from trials investigating this course of action.
Even though the statement of Schentag et al. that serial culturing would be appropriate for these types of trials, especially if they are regulatory, may be true, the ability to actually conduct such a trial is questionable at best. The patients in trials described by Schentag et al. often had endotracheal tubes inserted due to respiratory failure. As such, it was simple to obtain daily culture samples to monitor actual eradication time. However, this scenario, especially for any community-acquired respiratory tract infection, is highly impractical and nearly impossible -not just from the standpoint of obtaining the cultures, which would most often come from nonintubated individuals. The cultures themselves provide the biggest obstacle, as any single expectorated sputum specimen has a <50% chance of not only being evaluable, but actually growing anything more than upper respiratory flora. Thus, the problem is not growing an organism, it is determining which organism is responsible for the infection. If there is a <50%
The Annals of Pharmacotherapy ■ 2003 October, Volume 37 ■ 1519 www.theannals.com chance of obtaining anything valid from a single day's specimen, there is no guarantee that the lack of finding the identical isolate the following day is due to eradication or the luck of the draw. As such, criticizing investigators for using the most valid methods available to them as well as secondary measures is unfair and inappropriate.
A plethora of data from nonclinical models of infection, as well as data from human infections, 3,12 now supports different AUC/MIC break points for different pathogens. to demonstrate their point that the break points for gramnegative and gram-positive pathogens are the same. Yet, an AUC/MIC ratio of 0 -92 provided bacteriologic cure for 7 of 8 patients with S. pneumoniae; 7 of 7 were cured at ratios of 92.1-230, and 3 of 4 were cured at a ratio of >230.1. It is actually difficult to conclude anything based on these data since there are not enough failures to define the shoulder of the dose-response curve as all but 2 patients were bacteriologic cures, 1 of whom had an AUC/MIC >230.1. Ambrose et al. 12 reported the probability of bacteriologic eradication for S. pneumoniae in patients to be 64% if the unbound drug AUC/MIC was <33.7 (n = 4 failures), while the probability for successful eradication was 100% with an unbound drug AUC/MIC ≥33.7.
Schentag et al. may also indirectly provide supportive data for the lower pneumococcal break point in their own studies. These authors failed to correct for the impact of protein binding in the grepafloxacin studies. 13 Craig and Andes 15 clearly demonstrated better correlation between both survival and reduction in cfu/thigh endpoints when unbound drug exposures were used as opposed to total drug. To this end, Figure 3 in the Schentag et al. article separates time to eradication based on the probability of attaining total drug AUC/MIC <100 and ≥100 for 12 patients with S. pneumoniae treated with grepafloxacin. When one properly corrects for grepafloxacin's protein binding (55%) in that study, the AUC/MIC break point becomes 45 rather than 100; thus, attaining an AUC/MIC ≥45 rather than 100 is associated with the quickest eradication rates. It comes full circle after all, as Schentag 16 stated in an editorial: "There is far more agreement than disagreement in this discipline."
Much of the latter third of the article by Schentag et al. 1 has a significant bias toward drugs that they have supported in a consulting manner both in the past and presently, which is inappropriate. Contrary to what Schentag et al. state, the most recent American Thoracic Society community-acquired pneumonia treatment guidelines 17 do indeed include levofloxacin as a potential fluoroquinolone treat-ment option. Although the authors may have quoted 2 reported failures and the low (by their standards) AUC/MIC ratios achieved to support the abandonment of levofloxacin, it is difficult to support this contention when one considers the volume of prescriptions that the 2 failures being a numerator would be divided by. If one takes the 11.7 million prescriptions dispensed for levofloxacin in the US last year and assumes that one-third of them were for pneumococcal infections (marketed for respiratory tract infections, incidence of pneumococcus is ~30%), there should have been approximately 3.9 million failures. This therefore argues for the lower AUC/MIC ratios as being correct break points, the additivity or synergism of the immune response coming into play, or both. If one still insists on accepting a ratio of 250 being necessary for proper eradication, not only should levofloxacin always fail to work against pneumococcal infections, but it and the remainder of the fluoroquinolones should hardly ever successfully eradicate any pathogen. As an example, if one uses the 24-hour steadystate serum AUC of intravenous levofloxacin 500 mg given once daily, which is approximately 60 mg•h/L, the highest MIC of a pathogen that could be successfully eradicated is 0.25 mg/L. If one takes the 24-hour AUC of a 400-mg oral dose of moxifloxacin (~30 mg•h/L), the highest MIC that could be treated is 0.12 mg/L.
Based on these examples and the insistence of Schentag et al. on a break point of 250, not only ciprofloxacin, but rather the fluoroquinolones as a whole would need to be abandoned for the majority of community and nosocomially acquired infections, thereby relegating them to being no more than agents to treat urinary tract infections (UTIs), with the exception of moxifloxacin, which is inferior to approved comparators in UTIs as per the product label. As it is obvious from the literature that these antibiotics work for a multitude of infection types caused by a plethora of pathogens, the insistence on this AUC/MIC break point of 250 for all pathogens and infections and/or the use of serum concentrations to calculate exposure curves is in error. Also, it demonstrates that, for gram-positive infections, the lower break points that have been demonstrated repeatedly in the literature are most likely more appropriate.
The authors continue to quote misanalyzed data from their own center in this review. An example is the citation of in vivo development of bacterial resistance reported by Thomas et al. 18 This study purports to have found a relationship of an AUC/MIC ratio <100 and the development of bacterial resistance. A closer look at these data notes that at least 70 of the 131 isolates analyzed in that reference (Table  4 of Thomas et al.) were exposed to the β-lactam antibiotics cefmenoxime, ceftazidime, and piperacillin. The facts are clear and the concept well accepted that AUC/MIC is not the predictive pharmacodynamic variable for β-lactams, but rather the time that an antimicrobial agent concentration remains >MIC is the predictive pharmacodynamic index. 19 Thomas et al. 18 used an incorrect method of analysis, applying AUC/MIC to β-lactam activity; thus, the conclusions reached are questionable. Unfortunately, there are numerous other examples of data misinterpretation by Schentag et al.
The piece by Schentag et al. in this issue of The Annals is more a commentary piece than an article which reviews all the literature. Sadly, the article by Schentag et al. is an incomplete rendering of a large body of literature that is not supportive of his opinion. There is no room for and can be no tolerance of one professional trying to settle the score with another in a very public manner. The group in Buffalo as well as other groups worldwide have worked hard to bring antimicrobial pharmacodynamic applications into the regulatory and clinical setting. Such actions as written in the paper of Schentag et al. and as cited in this editorial are inappropriate and set the science of antimicrobial pharmacokinetics/pharmacodynamics back, as it publicizes emotionally driven, intellectually incomplete comments to regulatory agencies and other professionals alike. If professionals working in this area cannot discuss these issues in a complete and scientifically accurate fashion, what is the reader of such articles to think?
